{"id":355046,"date":"2026-11-19T13:56:06","date_gmt":"2026-11-19T08:26:06","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=355046"},"modified":"2026-11-19T13:56:06","modified_gmt":"2026-11-19T08:26:06","slug":"anthem-biosciences-analyst-review","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/anthem-biosciences-analyst-review\/","title":{"rendered":"Anthem Biosciences Analyst Review 2027: Q2 Profit Beat Keeps Brokers at \u20b91,000 to \u20b91,050"},"content":{"rendered":"<div style=\"background:#E8F1FF;border-left:5px solid #1565C0;padding:16px 20px;margin:0 0 20px 0;border-radius:6px;\">\n<p><strong>Anthem Biosciences Stock Snapshot (18 Nov 2026 close)<\/strong><\/p>\n<ul>\n<li><strong>Current Market Price (CMP):<\/strong> \u20b9914.35<\/li>\n<li><strong>52-Week High \/ Low:<\/strong> \u20b9989.10 \/ \u20b9579.15<\/li>\n<li><strong>Market Capitalisation:<\/strong> \u20b951,510 crore<\/li>\n<li><strong>P\/E Ratio vs Industry P\/E:<\/strong> 83.9 vs 40.1<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Revenue:<\/strong> \u20b9652.93 crore<\/li>\n<li><strong>Latest Quarter (Q2 FY27) Net Profit:<\/strong> \u20b9211.46 crore<\/li>\n<\/ul>\n<\/div>\n<div style=\"background:#F0F9FF;border-left:5px solid #2E7D32;padding:16px 20px;margin:0 0 20px 0;\">\n<p><strong>Quick Answer:<\/strong> The <strong>Anthem Biosciences analyst review 2027<\/strong> shows a profit beat and steady brokerage support. Q2 FY27 total income rose about 9% to \u20b9652.93 crore, EBITDA rose about 24% to \u20b9330.39 crore and net profit rose about 22% to \u20b9211.46 crore, ahead of PL Capital&#8217;s estimate. PL Capital holds Buy with a \u20b91,050 target (4 November 2026), JPMorgan holds Buy at \u20b91,000 (November 2026) and Jefferies has \u20b91,050 (August 2026). At \u20b9914.35, the <strong>Anthem Biosciences share price target 2027<\/strong> range implies about 9% to 15% upside.<\/p>\n<\/div>\n<p>The <strong>Anthem Biosciences analyst review 2027<\/strong> covers a Bengaluru-based contract research, development and manufacturing company, known as a CRDMO, that makes drug ingredients for global pharma and biotech clients. Readers searching for an <strong>Anthem Biosciences share price target 2027<\/strong> will find several named <strong>brokerage<\/strong> targets, all of them above the current price.<\/p>\n<p><a href=\"https:\/\/univest.in\/stocks\/anthem\/anthem-biosciences-ltd-share-price-today\">Anthem Biosciences<\/a> closed at \u20b9914.35 on 18 November 2026, about 8% below its 52-week high of \u20b9989.10 and about 58% above its low of \u20b9579.15. This Anthem Biosciences analyst review 2027 covers what brokers say, the September quarter and what will drive the <strong>Anthem Biosciences stock outlook 2027<\/strong>.<\/p>\n<p><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=anthem-biosciences-analyst-review\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-analyst-review\/#What_Brokerages_Say_in_the_Anthem_Biosciences_Analyst_Review_2027\" title=\"What Brokerages Say in the Anthem Biosciences Analyst Review 2027\">What Brokerages Say in the Anthem Biosciences Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-analyst-review\/#Q2_FY27_Results_in_the_Anthem_Biosciences_Analyst_Review_2027\" title=\"Q2 FY27 Results in the Anthem Biosciences Analyst Review 2027\">Q2 FY27 Results in the Anthem Biosciences Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-analyst-review\/#How_Anthem_Biosciences_Makes_Money\" title=\"How Anthem Biosciences Makes Money\">How Anthem Biosciences Makes Money<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-analyst-review\/#Growth_Triggers_in_the_Anthem_Biosciences_Analyst_Review_2027\" title=\"Growth Triggers in the Anthem Biosciences Analyst Review 2027\">Growth Triggers in the Anthem Biosciences Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-analyst-review\/#Key_Risks_in_the_Anthem_Biosciences_Analyst_Review_2027\" title=\"Key Risks in the Anthem Biosciences Analyst Review 2027\">Key Risks in the Anthem Biosciences Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-analyst-review\/#Anthem_Biosciences_Analyst_Review_2027_Stock_at_a_Glance\" title=\"Anthem Biosciences Analyst Review 2027: Stock at a Glance\">Anthem Biosciences Analyst Review 2027: Stock at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-analyst-review\/#Shareholding_Trend\" title=\"Shareholding Trend\">Shareholding Trend<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-analyst-review\/#What_to_Watch_After_the_Anthem_Biosciences_Analyst_Review_2027\" title=\"What to Watch After the Anthem Biosciences Analyst Review 2027\">What to Watch After the Anthem Biosciences Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-analyst-review\/#Final_Word_on_the_Anthem_Biosciences_Analyst_Review_2027\" title=\"Final Word on the Anthem Biosciences Analyst Review 2027\">Final Word on the Anthem Biosciences Analyst Review 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-analyst-review\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-analyst-review\/#What_does_the_Anthem_Biosciences_analyst_review_2027_show\" title=\"What does the Anthem Biosciences analyst review 2027 show?\">What does the Anthem Biosciences analyst review 2027 show?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-analyst-review\/#What_is_the_Anthem_Biosciences_share_price_target_2027_from_brokerages\" title=\"What is the Anthem Biosciences share price target 2027 from brokerages?\">What is the Anthem Biosciences share price target 2027 from brokerages?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-analyst-review\/#Why_did_Anthem_Biosciences_profit_beat_estimates_in_Q2_FY27\" title=\"Why did Anthem Biosciences profit beat estimates in Q2 FY27?\">Why did Anthem Biosciences profit beat estimates in Q2 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-analyst-review\/#Why_was_the_June_quarter_weak_for_Anthem_Biosciences\" title=\"Why was the June quarter weak for Anthem Biosciences?\">Why was the June quarter weak for Anthem Biosciences?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-analyst-review\/#Is_Anthem_Biosciences_stock_expensive_based_on_the_Anthem_Biosciences_analyst_review_2027\" title=\"Is Anthem Biosciences stock expensive based on the Anthem Biosciences analyst review 2027?\">Is Anthem Biosciences stock expensive based on the Anthem Biosciences analyst review 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-analyst-review\/#What_risks_does_the_Anthem_Biosciences_analyst_review_2027_highlight\" title=\"What risks does the Anthem Biosciences analyst review 2027 highlight?\">What risks does the Anthem Biosciences analyst review 2027 highlight?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/anthem-biosciences-analyst-review\/#What_should_investors_track_after_the_Anthem_Biosciences_analyst_review_2027\" title=\"What should investors track after the Anthem Biosciences analyst review 2027?\">What should investors track after the Anthem Biosciences analyst review 2027?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Brokerages_Say_in_the_Anthem_Biosciences_Analyst_Review_2027\"><\/span><strong>What Brokerages Say in the Anthem Biosciences Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Brokerage<\/th>\n<th>Rating<\/th>\n<th>Target Price<\/th>\n<th>Date<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>PL Capital (Prabhudas Lilladher)<\/td>\n<td>Buy<\/td>\n<td>\u20b91,050<\/td>\n<td>4 November 2026<\/td>\n<\/tr>\n<tr>\n<td>JPMorgan<\/td>\n<td>Buy<\/td>\n<td>\u20b91,000<\/td>\n<td>November 2026<\/td>\n<\/tr>\n<tr>\n<td>Jefferies<\/td>\n<td>Buy<\/td>\n<td>\u20b91,050<\/td>\n<td>August 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>PL Capital&#8217;s <strong>Q2 FY27<\/strong> note said profit of about \u20b9210 crore came in well above its estimate of about \u20b9180 crore, helped partly by making an intermediate in-house that Anthem earlier bought from outside. JPMorgan, which had a \u20b9900 target in July, moved to \u20b91,000 and kept that view after the results.<\/p>\n<p>Jefferies started coverage in August 2026 with a \u20b91,050 target. With the stock at \u20b9914.35, the named <strong>brokerage<\/strong> targets in this Anthem Biosciences analyst review 2027 sit between about 9% and 15% above the market price.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q2_FY27_Results_in_the_Anthem_Biosciences_Analyst_Review_2027\"><\/span><strong>Q2 FY27 Results in the Anthem Biosciences Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Total Income<\/th>\n<th>EBITDA<\/th>\n<th>Net Profit<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Sep 2026 (Q2 FY27)<\/td>\n<td>\u20b9652.93 crore<\/td>\n<td>\u20b9330.39 crore<\/td>\n<td>\u20b9211.46 crore<\/td>\n<\/tr>\n<tr>\n<td>Jun 2026 (Q1 FY27)<\/td>\n<td>\u20b9443.11 crore<\/td>\n<td>\u20b9175.46 crore<\/td>\n<td>\u20b9119.94 crore<\/td>\n<\/tr>\n<tr>\n<td>Mar 2026 (Q4 FY26)<\/td>\n<td>\u20b9662.15 crore<\/td>\n<td>\u20b9318.43 crore<\/td>\n<td>\u20b9189.76 crore<\/td>\n<\/tr>\n<tr>\n<td>Sep 2025 (Q2 FY26)<\/td>\n<td>\u20b9598.26 crore<\/td>\n<td>\u20b9266.13 crore<\/td>\n<td>\u20b9173.43 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Total income rose about 9% from a year ago, while <strong>EBITDA<\/strong> rose about 24%, lifting the <strong>EBITDA margin<\/strong> to about 51% from about 44%. <strong>Net profit<\/strong> grew about 22% to \u20b9211.46 crore, the highest quarterly profit in the table.<\/p>\n<p>The June quarter was weak because customer shipments shifted into later quarters, and income bounced back by about 47% in September. For the Anthem Biosciences analyst review 2027, the main point is that margins rose even on modest yearly sales growth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Anthem_Biosciences_Makes_Money\"><\/span><strong>How Anthem Biosciences Makes Money<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Anthem works with drug developers from early research through commercial supply.<\/p>\n<ul>\n<li><strong>Research services:<\/strong> chemistry and biology work for clients&#8217; early drug programmes.<\/li>\n<li><strong>Development and manufacturing:<\/strong> scaling up and producing active ingredients and intermediates under contract.<\/li>\n<li><strong>Commercial supply:<\/strong> long-term manufacturing for approved molecules.<\/li>\n<li><strong>Specialty ingredients:<\/strong> fermentation-based products sold separately.<\/li>\n<\/ul>\n<p>FY26 revenue was about \u20b92,280 crore with profit of about \u20b9592 crore, up from \u20b91,930 crore and \u20b9451 crore in FY25. Operating cash flow jumped to about \u20b9845 crore in FY26 from \u20b9271 crore. That track record is the base of this Anthem Biosciences analyst review 2027.<\/p>\n<p>Contract manufacturers earn more as client molecules move from trials into commercial sales, because volumes rise and pricing is locked into longer contracts. That shift is why brokers value the stock at a premium to domestic generic drug makers, and why <strong>quarterly results<\/strong> can swing with the timing of large orders.<\/p>\n<p>Shipment timing is the key thing to understand when reading Anthem&#8217;s quarterly numbers. A few large orders can move from one quarter to the next, which is why the June quarter looked weak and the September quarter strong. Looking at half-year or full-year totals gives a clearer picture than any single quarter, and H1 FY27 profit of about \u20b9331 crore already equals more than half of the full FY26 profit of about \u20b9592 crore.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Growth_Triggers_in_the_Anthem_Biosciences_Analyst_Review_2027\"><\/span><strong>Growth Triggers in the Anthem Biosciences Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Margin strength:<\/strong> <strong>EBITDA<\/strong> margin of about 51% in <strong>Q2 FY27<\/strong>.<\/li>\n<li><strong>In-sourcing:<\/strong> making intermediates in-house helped profit beat estimates.<\/li>\n<li><strong>Capacity:<\/strong> brokers track the new Unit IV greenfield plant for future volumes.<\/li>\n<li><strong>Molecule pipeline:<\/strong> more client products reaching commercial stage lifts recurring revenue.<\/li>\n<li><strong>Cash generation:<\/strong> FY26 operating cash flow of about \u20b9845 crore supports the Anthem Biosciences share price target 2027 case.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_in_the_Anthem_Biosciences_Analyst_Review_2027\"><\/span><strong>Key Risks in the Anthem Biosciences Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Rich valuation:<\/strong> a trailing <strong>P\/E<\/strong> near 84 against an industry figure of about 40.<\/li>\n<li><strong>Product concentration:<\/strong> Nomura flagged reliance on a few key products as the main risk.<\/li>\n<li><strong>Lumpy quarters:<\/strong> the June quarter showed how shipment timing can swing results.<\/li>\n<li><strong>Client risk:<\/strong> delays or failures in client drug programmes can cut orders.<\/li>\n<li><strong>Currency and global demand:<\/strong> most business comes from overseas clients, a factor in the Anthem Biosciences analyst review 2027.<\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/univest.in\/screeners\">Compare Anthem Biosciences With Other Pharma Stocks on the Univest Screener<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Anthem_Biosciences_Analyst_Review_2027_Stock_at_a_Glance\"><\/span><strong>Anthem Biosciences Analyst Review 2027: Stock at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Share Price (18 Nov 2026 close)<\/td>\n<td>\u20b9914.35<\/td>\n<\/tr>\n<tr>\n<td>52-Week High \/ Low<\/td>\n<td>\u20b9989.10 \/ \u20b9579.15<\/td>\n<\/tr>\n<tr>\n<td>Market Capitalisation<\/td>\n<td>\u20b951,510 crore<\/td>\n<\/tr>\n<tr>\n<td>P\/E (TTM)<\/td>\n<td>83.9<\/td>\n<\/tr>\n<tr>\n<td>Industry P\/E<\/td>\n<td>40.1<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>15.7<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>18.7%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.01<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>\u20b910.90<\/td>\n<\/tr>\n<tr>\n<td>FY26 Revenue \/ Net Profit<\/td>\n<td>\u20b92,280 crore \/ \u20b9592 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The <strong>P\/E<\/strong> of about 84 is roughly double the industry level, so the stock already prices in strong growth. The balance sheet is almost debt-free. Compared with the <a href=\"https:\/\/univest.in\/indices\/nifty-pharma\/nifty-pharma-share-price-today\">Nifty Pharma<\/a> index, Anthem trades as a premium CRDMO name, which this Anthem Biosciences analyst review 2027 treats as both a strength and a risk.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Shareholding_Trend\"><\/span><strong>Shareholding Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Holder<\/th>\n<th>Sep 2025<\/th>\n<th>Sep 2026<\/th>\n<th>Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Promoters<\/td>\n<td>74.69%<\/td>\n<td>71.40%<\/td>\n<td>Down 3.29 points<\/td>\n<\/tr>\n<tr>\n<td>Foreign Investors (FII)<\/td>\n<td>1.67%<\/td>\n<td>3.79%<\/td>\n<td>Up 2.12 points<\/td>\n<\/tr>\n<tr>\n<td>Domestic Institutions (DII)<\/td>\n<td>7.22%<\/td>\n<td>12.10%<\/td>\n<td>Up 4.88 points<\/td>\n<\/tr>\n<tr>\n<td>Public<\/td>\n<td>16.42%<\/td>\n<td>12.70%<\/td>\n<td>Down 3.72 points<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Founder Ajay Bhardwaj holds about 42.4% and the <strong>promoter<\/strong> group 71.4%. Institutions raised their combined stake from about 8.9% to 15.9% over the year, a positive signal in the Anthem Biosciences analyst review 2027.<\/p>\n<p><strong><a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a><\/strong><\/p>\n<p><strong><a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_to_Watch_After_the_Anthem_Biosciences_Analyst_Review_2027\"><\/span><strong>What to Watch After the Anthem Biosciences Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Q3 FY27 results:<\/strong> whether income stays above \u20b9600 crore after the strong September quarter.<\/li>\n<li><strong>Margins:<\/strong> <strong>EBITDA<\/strong> margin holding near 50%.<\/li>\n<li><strong>Unit IV plant:<\/strong> timing of commercial production.<\/li>\n<li><strong>New contracts:<\/strong> additions to late-stage and commercial molecules.<\/li>\n<li><strong>Target revisions:<\/strong> moves above \u20b91,050 would lift the Anthem Biosciences share price target 2027 range.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Final_Word_on_the_Anthem_Biosciences_Analyst_Review_2027\"><\/span><strong>Final Word on the Anthem Biosciences Analyst Review 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Anthem Biosciences analyst review 2027<\/strong> shows a high-margin CRDMO that beat profit estimates in <strong>Q2 FY27<\/strong>, with PL Capital, JPMorgan and Jefferies all holding Buy calls between \u20b91,000 and \u20b91,050. The main debate is valuation, with the stock near 84 times trailing earnings.<\/p>\n<p>The <strong>Anthem Biosciences stock outlook 2027<\/strong> depends on steady order flow, margins near 50% and new capacity coming on time. Univest does not give a buy or sell call.<\/p>\n<div style=\"background:#FFF5F5;border-left:5px solid #C62828;padding:14px 18px;margin:24px 0;\">\n<p style=\"color:#C62828;\"><strong>Disclaimer:<\/strong> This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div class=\"faq-schema\">\n<h3><span class=\"ez-toc-section\" id=\"What_does_the_Anthem_Biosciences_analyst_review_2027_show\"><\/span><strong>What does the Anthem Biosciences analyst review 2027 show?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>It shows a strong September quarter. Q2 FY27 net profit rose about 22% to \u20b9211.46 crore and EBITDA rose about 24% to \u20b9330.39 crore. EBITDA margin reached about 51%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Anthem_Biosciences_share_price_target_2027_from_brokerages\"><\/span><strong>What is the Anthem Biosciences share price target 2027 from brokerages?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>PL Capital has a \u20b91,050 target from 4 November 2026 and JPMorgan has \u20b91,000 from November 2026. Jefferies set \u20b91,050 in August 2026. Against \u20b9914.35, these imply about 9% to 15% upside.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_Anthem_Biosciences_profit_beat_estimates_in_Q2_FY27\"><\/span><strong>Why did Anthem Biosciences profit beat estimates in Q2 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>PL Capital said profit of about \u20b9210 crore beat its estimate of about \u20b9180 crore. Part of the gain came from making an intermediate in-house. Margins rose to about 51% from about 44% a year earlier.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_was_the_June_quarter_weak_for_Anthem_Biosciences\"><\/span><strong>Why was the June quarter weak for Anthem Biosciences?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Customer shipments moved into later quarters, so Q1 FY27 income fell to \u20b9443.11 crore. Profit that quarter was \u20b9119.94 crore. Income rebounded to \u20b9652.93 crore in September.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Anthem_Biosciences_stock_expensive_based_on_the_Anthem_Biosciences_analyst_review_2027\"><\/span><strong>Is Anthem Biosciences stock expensive based on the Anthem Biosciences analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The trailing P\/E is about 84 against an industry P\/E of about 40. Price to book is about 15.7. Brokers justify the premium with high margins and a strong CRDMO pipeline.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_does_the_Anthem_Biosciences_analyst_review_2027_highlight\"><\/span><strong>What risks does the Anthem Biosciences analyst review 2027 highlight?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The main risks are a rich valuation, reliance on a few key products and lumpy shipments. Nomura flagged product concentration as its main concern. Most revenue comes from overseas clients.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_should_investors_track_after_the_Anthem_Biosciences_analyst_review_2027\"><\/span><strong>What should investors track after the Anthem Biosciences analyst review 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track whether Q3 FY27 income stays above \u20b9600 crore with margins near 50%. Watch the Unit IV plant timeline and new client contracts. Any target change above \u20b91,050 would matter.<\/p>\n<\/div>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What does the Anthem Biosciences analyst review 2027 show?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It shows a strong September quarter. Q2 FY27 net profit rose about 22% to \u20b9211.46 crore and EBITDA rose about 24% to \u20b9330.39 crore. EBITDA margin reached about 51%.\"}},{\"@type\":\"Question\",\"name\":\"What is the Anthem Biosciences share price target 2027 from brokerages?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"PL Capital has a \u20b91,050 target from 4 November 2026 and JPMorgan has \u20b91,000 from November 2026. Jefferies set \u20b91,050 in August 2026. Against \u20b9914.35, these imply about 9% to 15% upside.\"}},{\"@type\":\"Question\",\"name\":\"Why did Anthem Biosciences profit beat estimates in Q2 FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"PL Capital said profit of about \u20b9210 crore beat its estimate of about \u20b9180 crore. Part of the gain came from making an intermediate in-house. Margins rose to about 51% from about 44% a year earlier.\"}},{\"@type\":\"Question\",\"name\":\"Why was the June quarter weak for Anthem Biosciences?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Customer shipments moved into later quarters, so Q1 FY27 income fell to \u20b9443.11 crore. Profit that quarter was \u20b9119.94 crore. Income rebounded to \u20b9652.93 crore in September.\"}},{\"@type\":\"Question\",\"name\":\"Is Anthem Biosciences stock expensive based on the Anthem Biosciences analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The trailing P\/E is about 84 against an industry P\/E of about 40. Price to book is about 15.7. Brokers justify the premium with high margins and a strong CRDMO pipeline.\"}},{\"@type\":\"Question\",\"name\":\"What risks does the Anthem Biosciences analyst review 2027 highlight?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The main risks are a rich valuation, reliance on a few key products and lumpy shipments. Nomura flagged product concentration as its main concern. Most revenue comes from overseas clients.\"}},{\"@type\":\"Question\",\"name\":\"What should investors track after the Anthem Biosciences analyst review 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Track whether Q3 FY27 income stays above \u20b9600 crore with margins near 50%. Watch the Unit IV plant timeline and new client contracts. Any target change above \u20b91,050 would matter.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Anthem Biosciences grew Q2 FY27 profit about 22% to \u20b9211 crore on an EBITDA margin above 50%, beating PL Capital&#8217;s estimate. PL Capital holds a \u20b91,050 target and JPMorgan \u20b91,000. We review brokerage views, results, the CRDMO model, valuation and risks.<\/p>\n","protected":false},"author":38,"featured_media":355045,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[24444,4341,9113,26186],"class_list":["post-355046","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-24444","tag-analyst-review","tag-anthem-biosciences","tag-pharmaceuticals-crdmo"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["355045"],"rank_math_title":["Anthem Biosciences Share Price Target 2027: Brokers"],"rank_math_description":["Anthem Biosciences analyst review 2027: PL Capital \u20b91,050, JPMorgan \u20b91,000, Q2 FY27 profit up 22% to \u20b9211 crore, 51% EBITDA margin, CRDMO drivers and risks."],"rank_math_focus_keyword":["Anthem Biosciences analyst review 2027"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/anthem-biosciences-analyst-review-2027-q2-profit-beat-keeps-brokers-at-1-000-to.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355046","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=355046"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355046\/revisions"}],"predecessor-version":[{"id":355048,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/355046\/revisions\/355048"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/355045"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=355046"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=355046"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=355046"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}